XPH
SPDR S&P Pharmaceuticals ETF [XPH] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
XPH Stock Summary
Top 10 Correlated ETFs
XPH
Top 10 Correlated Stocks
XPH
In the News
Pharma ETFs in Focus Post Q3 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Making its debut on 06/19/2006, smart beta exchange traded fund SPDR S&P Pharmaceuticals ETF (XPH) provides investors broad exposure to the Health Care ETFs category of the market.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.
Pharma ETFs in Focus Post Q2 Earnings
Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
Cautious on Big Tech & AI? Try These Value-Focused Sector ETFs
Value-focused investing comes to rescue if high-growth sectors fail for some reasons.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Making its debut on 06/19/2006, smart beta exchange traded fund SPDR S&P Pharmaceuticals ETF (XPH) provides investors broad exposure to the Health Care ETFs category of the market.
XPH: Non-Diversified U.S.-Based Large-Cap Pharma ETF Isn't Very Attractive
XPH's consistent low yield and poor price growth (mostly negative) over both short-run as well as over long-run should be disheartening for investors. Expiration of a large number of patents within 2030, and narrow revenue stream expected from orphan drugs will impact the pharmaceutical industry. Revlimid, Januvia/Janumet, Reyvow, Bedaquiline, Keytruda, Opdivo, Eliquis, Ibrance, Stelara, Trulicity - all drugs are going to become off-patent by 2030.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the SPDR S&P Pharmaceuticals ETF (XPH), a passively managed exchange traded fund launched on 06/19/2006.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Launched on 06/19/2006, the SPDR S&P Pharmaceuticals ETF (XPH) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.
Pharma ETFs Gain Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
XPH Financial details
XPH Financial Performance
XPH Frequently Asked Questions
What is SPDR S&P Pharmaceuticals ETF stock symbol ?
SPDR S&P Pharmaceuticals ETF is a US stock and trading under the symbol XPH
What is SPDR S&P Pharmaceuticals ETF stock quote today ?
SPDR S&P Pharmaceuticals ETF stock price is $36.64 today.
Is SPDR S&P Pharmaceuticals ETF stock public?
Yes, SPDR S&P Pharmaceuticals ETF is a publicly traded company.
Company Profile
- Volume Average 46.07K
- Market Capitalization 204.11M
- Headquarters US
- IPO Date 2006-06-22
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
